Interim results from a study led by the Duke Cancer Institute suggest that a drug combination that shows little overall survival benefit in white men with advanced prostate cancer has a far greater effect in Black men with the disease.

Funded by Janssen Pharmaceuticals, the study known as Panther, administered the hormone therapies apalutamide and abiraterone acetate plus prednisone to parallel groups of Black and white participants with metastatic prostate cancer.

Two years from the start of treatment with the two hormonal therapies, only 14% of Black study participants have died, compared to 33% of the white participants.

Read the full article here.